New Clues to Schizophrenia

by Dr. Trupti Shirole on  March 15, 2017 at 9:41 AM Mental Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

Schizophrenia is one of the most disabling psychiatric diseases and affects approximately 1% of the population. It's onset commonly takes place in late adolescence and is often a life-long condition with symptoms such as delusions, hallucinations, and anxiety.
New Clues to Schizophrenia
New Clues to Schizophrenia

The disease mechanisms are largely unknown, which has hampered the development of new drugs. The drugs currently available are designed to alleviate the symptoms, but are only partly successful, as only 20% of the patients become symptom-free.

Researchers at Karolinska Institutet collaborating in the large-scale Karolinska Schizophrenia Project are taking an integrative approach to unravel the disease mechanisms of schizophrenia. In the very first results now presented in the prestigious scientific journal Molecular Psychiatry, the researchers show that patients with schizophrenia have lower levels of the vital neurotransmitter GABA as well as changes in the brain's immune cells.

The Karolinska Schizophrenia Project (KaSP) brings together researchers from a number of different scientific disciplines to build up a comprehensive picture of the disease mechanisms and to discover new targets for drug therapy. Patients with an acute first-episode psychosis are recruited and undergo extensive tests and investigations. Cognitive function, genetic variation, biochemical anomalies as well as brain structure and function are analyzed using the latest techniques and then compared with healthy peers.

The first results from the project are now presented in two studies published in the journal Molecular Psychiatry. One of the studies shows that patients with newly debuted schizophrenia have lower levels of the neurotransmitter GABA in their cerebrospinal fluid than healthy people and that the lower the concentration of GABA the more serious their symptoms are.

GABA is involved in most brain functions and along with glutamate it accounts for almost 90% of all signal transmission. While glutamate stimulates brain activity, GABA inhibits it, and the two neurotransmitters interact with each other.

"Over the years, animal studies have suggested a link between decreased levels of GABA and schizophrenia," says Professor Göran Engberg at Karolinska Institutet's Department of Physiology and Pharmacology. "Our results are important because they clinically substantiate this hypothesis."

The other study used the imaging technique of positron emission tomography (PET) to show that patients with untreated schizophrenia have lower levels of TSPO (translocator protein), which is expressed on immune cells such as microglia and astrocytes.

"Our interpretation of the results is an altered function of immune cells in the brain in early-stage schizophrenia," says Senior lecturer Simon Cervenka at Karolinska Institutet's Department of Clinical Neuroscience.

The results of the two studies provide new clues to the pathological mechanisms of schizophrenia, but it is unclear if the changes are the cause or the result of the disease. Follow-up studies are now underway to examine what causes the anomalies and how these biological processes can be influenced to change the progression of the disease.

KaSP is a collaboration between clinical and preclinical research groups at Karolinska Institutet and four psychiatric clinics under Stockholm County Council.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Schizophrenia Mental Health - Neurosis vs Psychosis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...